Pfizer Reports $62.6 Billion Revenue in 2025 and Returns $9.8 Billion to Shareholders

Pfizer (PFE) concluded the 2025 fiscal year with solid financial results, reporting total annual revenue of $62.6 billion. In the fourth quarter alone, the pharmaceutical giant generated $17.56 billion in revenue, reflecting a successful transition away from pandemic-era products. Excluding COVID-19 related segments, the company achieved a 6% growth in operational revenue, driven by its core portfolio and recent strategic acquisitions. Demonstrating its commitment to shareholder value, Pfizer returned approximately $9.8 billion through cash dividends during the year. The company’s strategic focus has now shifted toward its obesity pipeline and the integration of Seagen and Metsera, alongside AI-driven operational enhancements. These results signal financial stability and a successful pivot toward long-term growth drivers within the healthcare sector.